Newsroom

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery.

read more +
Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

Legislative and health policy expert brings extensive private and public sector experience

read more +
Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting

MENLO PARK, Calif.— March 2, 2022 — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI® Surgical System will be presented at the 2022 American Glaucoma Society (AGS) Annual Meeting. The conference […]

read more +
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma

read more +
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Label expansion for evaporative dry eye due to MGD will support further efforts to drive patient access to insurance-covered TearCare treatments

read more +
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference. A recording of the fireside chat will be […]

read more +
Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations

read more +
Sight Sciences Reports Third Quarter 2021 Financial Results

Unknown Sight Sciences Reports Third Quarter 2021 Financial Results   MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended September 30, 2021.   Recent […]

read more +